Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 8 B, 2009, Pages 1977-1986

  Barletta, Justine A ^a   Perner, Sven ^a   Iafrate, A John ^b   Yeap, Beow Y ^b   Weir, Barbara A ^c   Johnson, Laura A ^a   Johnson, Bruce E ^c   Meyerson, Matthew ^c   Rubin, Mark A ^a   Travis, William D ^d   Loda, Massimo ^a,c   Chirieac, Lucian R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Lung adenocarcinoma; Survival; TTF 1

Indexed keywords

NUCLEAR PROTEIN; THYROID NUCLEAR FACTOR 1; TRANSCRIPTION FACTOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; TRANSCRIPTION FACTORS;

EID: 69349095714     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00594.x     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008 58 : 71 96.
2. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 132 : 29S 55S.
3. Ettinger DS, Bepler G, Bueno R, et al. Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 4 : 548 582.
4. Gabrielson E. Worldwide trends in lung cancer pathology. Respirology. 2006 11 : 533 538.
5. Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006 355 : 1763 1771.
6. Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging manual. 6th ed. New York, NY : Springer 2002. pp. 91 8.
7. Detterbeck FC. Lumping, splitting, and sorting. J Thorac Oncol. 2007 2 : 581 582.
8. Ikeda K, Clark JC, Shaw-White JR, et al. Gene structure and expression of human thyroid transcription factor-1 in respiratory epithelial cells. J Biol Chem. 1995 270 : 8108 8114.
9. Kimura S, Hara Y, Pineau T, et al. The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev. 1996 10 : 60 9.
10. Minoo P, Su G, Drum H, et al. Defects in tracheoesophageal and lung morphogene sis in Nkx2.1(-/-) mouse embryos. Dev Biol. 1999 209 : 60 71.
11. Yuan B, Li C, Kimura S, et al. Inhibition of distal lung morphogenesis in Nkx2.1(-/-) embryos. Dev Dyn. 2000 217 : 180 190.
12. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B. Histopathology. 2000 36 : 8 16.
13. Stenhouse G, Fyfe N, King G, et al. Thyroid transcription factor 1 in pulmonary adenocarcinoma. J Clin Pathol. 2004 57 : 383 387.
14. Au NH, Cheang M, Huntsman DG, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol. 2004 204 : 101 109.
15. Berghmans T, Paesmans M, Mascaux C, et al. Thyroid transcription factor 1 - a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol. 2006 17 : 1673 1676. (Pubitemid 44680888)
16. Haque AK, Syed S, Lele SM, et al. Immunohistochemical study of thyroid transcription factor-1 and HER2/neu in non-small cell lung cancer: strong thyroid transcription factor-1 expression predicts better survival. Appl Immunohistochem Mol Morphol. 2002 10 : 103 109.
17. Myong NH. Thyroid transcription factor-1 (TTF-1) expression in human lung carcinomas: its prognostic implication and relationship with expressions of p53 and Ki-67 proteins. J Korean Med Sci. 2003 18 : 494 500.
18. Puglisi F, Barbone F, Damante G, et al. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma. Mod Pathol. 1999 12 : 318 324.
19. Shah L, Walter KL, Borczuk AC, et al. Expression of syndecan-1 and expression of epidermal growth factor receptor are associated with survival in patients with nonsmall cell lung carcinoma. Cancer. 2004 101 : 1632 1638.
20. Tan D, Li Q, Deeb G, et al. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum Pathol. 2003 34 : 597 604.
21. Barlesi F, Pinot D, Legoffic A, et al. Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer. 2005 93 : 450 452.
22. Pelosi G, Fraggetta F, Pasini F, et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas of the lung. Am J Surg Pathol. 2001 25 : 363 372.
23. Saad RS, Liu YL, Han H, et al. Prognostic significance of thyroid transcription factor-1 expression in both early-stage conventional adenocarcinoma and bronchioloalveolar carcinoma of the lung. Hum Pathol. 2004 35 : 3 7. (Pubitemid 38139310)
24. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature. 2007 450 : 893 898.
25. Lester SC. Manual of surgical pathology. 2nd ed. New York : Elsevier Churchill Livingstone 2006.
26. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Tumors of the lung. Pleura, Thymus and Heart. Lyon : IARC 2004. pp 497 516.
27. Motoi N, Szoke J, Riely GJ, et al. Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. Am J Surg Pathol. 2008 32 : 810 827.
28. Perner S, Wagner PL, Demichelis F, et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia. 2008 10 : 298 302.
29. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005 436 : 117 122.
30. Rubin MA, Varambally S, Beroukhim R, et al. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res. 2004 64 : 3814 3822.
31. Kendall J, Liu Q, Bakleh A, et al. Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci USA. 2007 104 : 16663 16668.